Neuroprotective Agents and Cerebral Ischaemia

1st Edition, Volume 40 - November 26, 1996

Editors: Richard C. Green, Ronald J. Bradley, Alan J. Cross, Robert Adron Harris, Peter Jenner

Hardback ISBN:

9 7 8 - 0 - 1 2 - 3 6 6 8 4 0 - 0

eBook ISBN:

9 7 8 - 0 - 0 8 - 0 8 5 7 7 4 - 9

Since 1959, International Review of Neurobiology has been a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. This… Read more

Neuroprotective Agents and Cerebral Ischaemia

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Since 1959, International Review of Neurobiology has been a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. This important serial is now being combined with Neuroscience Perspectives and Methods in Neurosciences. This combination results in a series that reaches a wider audience and publishes a greater number of thematic volumes.

Stroke is the third major cause of death in the western world, and recent data provide hope that treatments may soon be available. Written by world experts on the mechanisms involved in neurodegeneration, Neuroprotective Agents and Cerebral Ischaemia presents an up-to-date review of current research and developing therapies. This book is essential reading for all clinicians and researchers searching for neuroprotective drugs.

Richard C. Green

Affiliations and expertise

The Engineering Practice

Ronald J. Bradley

Affiliations and expertise

Louisiana State University Medical Center, School of Medicine, Baton Rouge, U.S.A.

Alan J. Cross

Alan Cross was at the MRC Clinical Research Centre, London, followed by two years as a lecturer in the Department of Physiology, University of Manchester. In 1980 he became Head of Pharmacology at the Aston Neuroscience Research Unit.

Affiliations and expertise

Astra Arcus USA, Rochester, New York, U.S.A.

Robert Adron Harris

Affiliations and expertise

University of Texas, Austin, U.S.A.

Peter Jenner

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.

Affiliations and expertise

Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UK